contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


magnasense-interim-report-april-june-2024

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Magnasense operates in the pharmaceutical industry. The company specializes in the research and development of various drug candidates. The product portfolio is broad and mainly includes drugs for the treatment of multiple sclerosis. In addition to the main business, associated ancillary services are offered. The business is run in collaboration with other pharmaceutical actors, where the largest presence is found in the Nordic region.

Magnasense

"As we conclude the second quarter of 2024, I am pleased to share with you several key developments that position Magnasense AB for continued growth and success in the evolving healthcare diagnostics...

<div class="mfn-preamble">"As we conclude the second quarter of 2024, I am pleased to share with you several key developments that position Magnasense AB for continued growth and success in the evolving healthcare diagnostics sector," said Marco Witteveen, CEO of Magnasense.</div><div class="mfn-body">April-June• Total income amounted to 3,1 (1,3) MSEK. • Loss before tax amounted to -8,4 (-16,4) MSEK. • Cash and cash equivalents at the end of the quarter was 2,4 (36,6) MSEK. • Earnings per share* -0,26 (-0,61) SEK. • Equity ratio** at 30 June 2024 was -24 (31) %.Significant events during the period April-June• Jens Umehag joined Magnasense AB as the new Chairman of the Board, succeeding Anders Ingvarsson. •Michael Schwartz and William Ferenczy joined the Board as new members. • The terms and conditions of series 2023/2025 convertible loan notes, issued by Atlas Special Opportunities, were amended to extend the term and adjust conversion requirements. • Further funding has been agreed through an additional 36 month secured MSEK 45 loan facility with Atlas Special Opportunities. • Magnasense AB successfully completed an additional milestone in its participation in the NIH RADx Tech Program. • The Company published a study in Multiple Sclerosis and Related Disorders journal.Significant events after the end of the period• Aegirbio AB changed its name to Magnasense AB, to better reflect core assets and focus. • Melissa Grant, Associate Professor at the University of Birmingham’s School of Dentistry, joined Magnasense’s Scientific Advisory Board. • Vicki Johnson joined Magnasense AB as interim CFO, succeeding Christel Dahlberg.* Earnings per share: Profit for the period divided by the weighted average number of shares, which as of 2024-06-30 amounted to 31,758,392 shares before dilution. The corresponding number for the same period in the previous year was 23,913,424 shares. ** Equity ratio: Equity divided by total capital.</div><div class="mfn-footer mfn-regulatory mfn-regulatory-mar">This information is information that Magnasense is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-08-23 08:00 CEST.</div><div class="mfn-footer mfn-contacts mfn-e503b60338ed">For additional information, please contact: Marco Witteveen, CEO, Magnasense AB Email: <a rel="noopener" href="mailto:ir@aegirbio.com">ir@magnasense.com</a> The Company’s Certified Adviser is Eminova Fondkommission AB | adviser@eminova.se</div><div class="mfn-footer mfn-about mfn-8c31e8f3e677">About Magnasense AB Magnasense is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, Magnasense was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Magnasense's website www.magnasense.com.</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments <a rel="noopener" href="https://storage.mfn.se/131b3635-678c-417d-ac8d-207838b9043e/magnasense-q2-2024-final-en.pdf" class="mfn-primary">Magnasense Q2 2024 Final (EN)</a></div>

Magnasense interim report April – June 2024

Wall Streetin arvostustasoihin verrattuna Eurooppakin näyttää nyt houkuttelevalta

Federal Reserven korkopäätös: Kiire loppui tähän

Lääkekehityssijoittaminen: Arvonluonti yrityskaupoilla ja lisensointisopimuksilla

EKP:n korkopäätös: Keskuspankki ilman rajoitteita

Euroalueen ostopäälliköt: Onks sen jälkeen vielä mäki?

Pysy ajantasalla Inderesin uutiskirjeillä